Västerås, Sweden, June 28, 2026 – Scandinavian Real Heart AB (publ) today announced that IP Australia, the Australian intellectual property rights agency, has granted Realheart a patent covering central aspects of the Realheart® TAH technology. The granted claims include the design and operation of the total artificial heart, as well as the integrated feedback mechanism that regulates the device's cardiac output. The patent remains in force in Australia until 2041.
Realheart is developing Realheart® TAH, the first total artificial heart designed to replicate the four-chamber structure and pumping cycle of the native human heart. The granted patent covers sensor technology that provides accurate pressure measurements, enabling real-time monitoring and automated control of artificial hearts and circulatory support systems, including Realheart® TAH.
Realheart® TAH is intended as a treatment alternative for patients awaiting a heart transplant, with the potential to improve quality of life during that period. The structural design of Realheart® TAH aims to reduce risk factors commonly associated with currently available artificial heart devices, such as stroke, internal bleeding, and anaemia.
Region: Australia
Patent number: 2021236921
Expiration date: March, 2041